Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Codrituzumab in Pediatric Patients With Relapsed or Refractory GPC3 Expressing Extra-cranial Solid Tumors
NCT04928677Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of codrituzumab in solid tumor and hepatoblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Jun 2021; status: recruiting.
02
Drugs
codrituzumab
03
Conditions
solid tumorhepatoblastoma
Beyond the preview
Go deeper on NCT04928677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04928677.